NEW YORK (GenomeWeb) – Q2 Solutions, a clinical trials laboratory services organization, said today that it has established a collaboration framework with Illumina for companion diagnostics development.
Under the terms of the agreement, Q2 Solutions will use Illumina's MiSeqDx instrument, which has US Food and Drug Administration 510(k) clearance, to develop next-generation sequencing-based companion diagnostics.
In an email to GenomeWeb, a company spokesman said the collaboration would also support the drug development programs of Q2 Solutions' sponsors, adding that the agreement with Illumina enables the company to develop, manufacture, distribute, and commercialize cleared or approved IVD kits, or companion diagnostics, in addition to its customary clinical trial work.
"The industry is quickly moving toward a world of precision medicine, and we believe companion diagnostics are key to unlocking a new future for patients who are battling diseases, such as cancer, where more targeted accurate therapies are critical," Q2 Solutions CEO Costa Panagos said in a statement.
Q2 Solutions is a clinical trials laboratory organization that was launched in 2015 as a joint venture by Quest Diagnostics and contract research organization Quintiles.